Natto: Release of NattoPharma 's results for Q3 2015 Wednesday 25. November 2015 at 08:00 hours

The same day, the company will hold a presentation of the quarterly results at the conference center of KS - Agenda, Haakon VII's gate 9, Oslo 25. November 2015 at 08.30 hours.

The presentation will be held by CEO Hogne Vik. Breakfast will be served.

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This
process generates a highly pure and bio-available form of vitamin K2,
menaquinone-7 (MK-7). MenaQ7 is the purest vitamin K2 on the market. MenaQ7 is
the only vitamin K2 with proven positive clinical health effects on bones and
the cardiovascular system. MenaQ7 vitamin K2 is the only vitamin K2 supported by
several granted patents on cardiovascular health worldwide.

About NattoPharma

As a biotechnology and nutraceutical company, NattoPharma is the worldwide
pioneer and innovator for developing, documenting and provide Vitamin K2
menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and
research substantiating clear positive clinical efficacy for bone and
cardiovascular health. NattoPharma has since 2007 been in a research and
development collaboration with VitaK, University in Maastricht, The Netherlands,
working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik

CEO, NattoPharma

Mobil: +47 97 53 53 26

Tags: